• Nebyly nalezeny žádné výsledky

Attachment I: Cost and Sales Analysis of PUDIS a.s. in thous. CZK Cost Analysis

N/A
N/A
Protected

Academic year: 2022

Podíl "Attachment I: Cost and Sales Analysis of PUDIS a.s. in thous. CZK Cost Analysis"

Copied!
1
0
0

Načítání.... (zobrazit plný text nyní)

Fulltext

(1)

Attachment I: Cost and Sales Analysis of PUDIS a.s. in thous. CZK Cost Analysis

PUDIS a.s.

2011 2012 2013 2014 2015

Production

consumption

24163 31% 30889 39% 24611 37% 25035 38% 39053 47%

Personnel

costs

50776 65% 46037 58% 40862 61% 39028 59% 41953 50%

Taxes and

fees

65 0% 70 0% 71 0% 73 0% 261 0%

Depreciation

1248 2% 856 1% 710 1% 915 1% 1360 2%

Other operating expanses

1473 2% 902 1% 459 1% 863 1% 837 1%

Total Costs

77725 100% 78754 100% 66713 100% 65914 100% 83464 100%

Figure 4.9 “Cost Analysis”

Sales analysis

PUDIS a.s. 2011 2012 2013 2014 2015

Revenues from own

products and services 71492 73455 63473 67466 91734 Revenues from sale of fixed

assets and material 11 39 1 432 4820

Total Revenues 71503 73494 63474 67898 96554

Figure 4.10 “Revenues Analysis”

Odkazy

Související dokumenty

This thesis estimates cost efficiency of 99 general hospitals in the Czech Repub- lic during 2001–2008 using Data Envelopment Analysis and Stochastic Frontier Analysis.. It

In the following section we provide the reader with the empirical analysis results. First, we present an overview of the results with respect to cost of equity value and cost of

But since hybrid backups can be deployed by both products Veeam and Acronis, I would make a decision based on a cost analysis of total cost of hybrid data backup solution for

Attachment B: Profit and Loss Account of

Attachment G: Horizontal Analysis of PUDIS a.s.. CZK Horizontal Analysis

Attachment H: Vertical Analysis of PUDIS a.s.. CZK Vertical Analysis

Attachment J: Competitor Analysis of PUDIS a.s... Rentability indicator: Return

Failure to recognize that observed negative health effects are caused by behavioral anomalies would lead the analyst to not include health gains in a benefit-cost analysis of